TCGA-A7-A0DC-01A-11R-A00Z-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 30
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.280
- SPERMATOGENESIS+0.210
- MITOTIC_SPINDLE+0.120
- UNFOLDED_PROTEIN_RESPONSE+0.120
- UV_RESPONSE_DN+0.120
- BILE_ACID_METABOLISM+0.090
- ANDROGEN_RESPONSE+0.060
- ESTROGEN_RESPONSE_EARLY+0.040
- HEME_METABOLISM+0.030
- TGF_BETA_SIGNALING+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.580
- ALLOGRAFT_REJECTION-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- INFLAMMATORY_RESPONSE-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.450
- TNFA_SIGNALING_VIA_NFKB-0.440
- COAGULATION-0.430
- APICAL_JUNCTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A13G-01A-11R-A13Q-07 | — | D | 0.903 |
| 2 | SRR29022828 | — | B | 0.890 |
| 3 | MDT-AP-0189 | Med | Medulloblastoma | 0.888 |
| 4 | SRR657325 | GTEX | — | 0.887 |
| 5 | SRR1322163 | GTEX | — | 0.886 |
| 6 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.883 |
| 7 | MNG45 | — | — | 0.883 |
| 8 | MBCProject_0343_T1_RNA | — | B | 0.883 |
| 9 | SRR655649 | GTEX | — | 0.882 |
| 10 | TCGA-A7-A3IZ-01A-11R-A213-07 | — | B | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |